AIRNA Closes $155M Series B Round to Fund ATTD Trial, Build Pipeline

AIRNA Closes $155M Series B Round to Fund ATTD Trial, Build Pipeline

RNA editing therapy developer AIRNA has closed on an oversubscribed $155 million Series B financing it said will help it advance its lead program targeting Alpha-1 antitrypsin deficiency (AATD) into a Phase I/II trial this year. The financing comes less than a year after AIRNA completed a $90 million Series A, of which $60 million was raised just last summer, and at a time when many other startups have struggled to raise venture capital. While p…